Internal Medicine, Pulmonary Disease · Kansas City, KS
NPI
1588758502
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3901 Rainbow Blvd, Mail Stop 3007
Kansas City, KS, 66160
Phone (913) 588-6046
Groups this clinician bills Medicare through
Medicare paid, 2024
$65K
1,704 services
Medicare patients, 2024
727
Average age 71
Drug cost, 2024
$6.1M
2,757 prescriptions
Company payments, 2025
$23K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark J Hamblin was code 94010 (pulmonary function testing), 333 times for 319 patients. In total Mark J Hamblin billed 1,704 services in 29 codes, and Medicare paid $65K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94010 Pulmonary Function Testing | Facility | 333 | 319 | $6.17 | $2,053 |
| 94729 Pulmonary Function Testing | Facility | 282 | 278 | $6.77 | $1,910 |
| 94726 Pulmonary Function Testing | Facility | 238 | 234 | $9.14 | $2,176 |
| 99215 Office E&M - Established | Office | 189 | 168 | $116.54 | $22K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 146 | 130 | $12.08 | $1,763 |
| 99233 Hospital E&M - Subsequent | Facility | 61 | 30 | $89.48 | $5,458 |
| 99215 Office E&M - Established | Facility | 59 | 55 | $102.40 | $6,042 |
| 94727 Pulmonary Function Testing | Facility | 53 | 53 | $9.22 | $489 |
| 94618 Pulmonary Function Testing | Facility | 39 | 37 | $16.67 | $650 |
| 99223 Hospital E&M - Initial | Facility | 39 | 39 | $130.68 | $5,097 |
| 94060 Pulmonary Function Testing | Facility | 36 | 36 | $7.88 | $284 |
| 99205 Office E&M - New | Office | 28 | 28 | $156.39 | $4,379 |
| 99214 Office E&M - Established | Office | 26 | 26 | $73.20 | $1,903 |
| 99291 Critical Care E&M | Facility | 21 | 15 | $148.81 | $3,125 |
| 99232 Hospital E&M - Subsequent | Facility | 15 | 13 | $60.03 | $900 |
By year: 2022 $59K for 1,244 services; 2023 $66K for 1,481 services; 2024 $65K for 1,704 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark J Hamblin prescribed most often to Medicare patients was Ofev (Nintedanib Esylate), with 428 prescriptions and refills. In total Mark J Hamblin wrote 2,757 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | 428 | 428 | 64 | $5.2M |
| Prednisone Generic | 386 | 780 | 142 | $3,320 |
| Mycophenolate Mofetil Generic | 268 | 352 | 57 | $24K |
| Azithromycin Generic | 182 | 328 | 71 | $2,784 |
| Pirfenidone Generic | 136 | 136 | 21 | $181K |
| Omeprazole Generic | 85 | 226 | 24 | $1,434 |
| Methotrexate Methotrexate Sodium | 82 | 176 | 21 | $1,570 |
| Azathioprine Generic | 76 | 150 | 19 | $5,384 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 63 | 99 | 30 | $2,215 |
| Pantoprazole Sodium Generic | 50 | 130 | 16 | $1,072 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 49 | 73 | 13 | $47K |
| Hydroxychloroquine Sulfate Generic | 45 | 69 | Under 11 | $1,477 |
| Furosemide Generic | 42 | 71 | 14 | $120 |
| Famotidine Generic | 41 | 124 | 17 | $387 |
| Breo Ellipta Fluticasone/Vilanterol | 33 | 57 | Under 11 | $21K |
Brand drugs: - claims; generic drugs: 1,981 claims; opioid claims: 75.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark J Hamblin $23K ($23K in general payments such as food, travel and fees) from 7 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $21K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.